期刊
CLINICAL NEUROPHYSIOLOGY
卷 120, 期 7, 页码 1313-1319出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.clinph.2009.05.008
关键词
Depression; EEG; LORETA; Placebo; Anterior cingulate
资金
- Eli Lilly and Company
- Wyeth-Ayerst Laboratories
- NSF IGERT fellowship
- Aspect Medical Systems, Inc
- National Center for Complementary and Alternative Medicine [R01 AT002479]
Objective: To assess whether pretreatment theta current density in the rostral anterior cingulate (rACC) and medial orbitofrontal cortex (mOFC) differentiates responders from non-responders to antidepressant medication or placebo in a double-blinded study. Methods: Pretreatment EEGs were collected from 72 subjects with Major Depressive Disorder (MDD) who participated in one of three placebo-controlled trials. Subjects were randomized to receive treatment with fluoxetine, venlafaxine, or placebo. Low-resolution brain electromagnetic tomography (LORETA) was used to assess theta current density in the rACC and mOFC. Results: Medication responders showed elevated rACC and mOFC theta current density compared to medication non-responders (rACC: p = 0.042; mOFC: p = 0.039). There was no significant difference in either brain region between placebo responders and placebo non-responders. Conclusions: Theta current density in the rACC and mOFC may be useful as a biomarker for prediction of response to antidepressant medication. Significance: This is the first double-blinded treatment study to examine pretreatment rACC and mOFC theta current density in relation to antidepressant response and placebo response. Results support the potential clinical utility of this approach for predicting clinical outcome to antidepressant treatments in MDD. (C) 2009 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据